JP2023085476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023085476A5 JP2023085476A5 JP2023061823A JP2023061823A JP2023085476A5 JP 2023085476 A5 JP2023085476 A5 JP 2023085476A5 JP 2023061823 A JP2023061823 A JP 2023061823A JP 2023061823 A JP2023061823 A JP 2023061823A JP 2023085476 A5 JP2023085476 A5 JP 2023085476A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr
- binding protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246113P | 2015-10-25 | 2015-10-25 | |
| US62/246,113 | 2015-10-25 | ||
| EP16305211.1 | 2016-02-24 | ||
| EP16305211 | 2016-02-24 | ||
| US201662322029P | 2016-04-13 | 2016-04-13 | |
| US62/322,029 | 2016-04-13 | ||
| US201662331169P | 2016-05-03 | 2016-05-03 | |
| US62/331,169 | 2016-05-03 | ||
| JP2018521308A JP7169190B2 (ja) | 2015-10-25 | 2016-10-24 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
| JP2021016190A JP7328267B2 (ja) | 2015-10-25 | 2021-02-04 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016190A Division JP7328267B2 (ja) | 2015-10-25 | 2021-02-04 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023085476A JP2023085476A (ja) | 2023-06-20 |
| JP2023085476A5 true JP2023085476A5 (OSRAM) | 2024-03-22 |
| JP7724814B2 JP7724814B2 (ja) | 2025-08-18 |
Family
ID=55588187
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521308A Active JP7169190B2 (ja) | 2015-10-25 | 2016-10-24 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
| JP2021016190A Active JP7328267B2 (ja) | 2015-10-25 | 2021-02-04 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
| JP2023061823A Active JP7724814B2 (ja) | 2015-10-25 | 2023-04-06 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521308A Active JP7169190B2 (ja) | 2015-10-25 | 2016-10-24 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
| JP2021016190A Active JP7328267B2 (ja) | 2015-10-25 | 2021-02-04 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US20190054182A1 (OSRAM) |
| EP (2) | EP3819310A1 (OSRAM) |
| JP (3) | JP7169190B2 (OSRAM) |
| KR (1) | KR102687212B1 (OSRAM) |
| CN (4) | CN116789841A (OSRAM) |
| AR (1) | AR106466A1 (OSRAM) |
| AU (2) | AU2016347058B2 (OSRAM) |
| BR (1) | BR112018008011A2 (OSRAM) |
| CA (1) | CA3002664A1 (OSRAM) |
| CL (1) | CL2018001065A1 (OSRAM) |
| CO (1) | CO2018005337A2 (OSRAM) |
| CR (1) | CR20180288A (OSRAM) |
| DO (1) | DOP2018000102A (OSRAM) |
| EA (1) | EA201891028A1 (OSRAM) |
| ES (1) | ES2894304T3 (OSRAM) |
| HR (1) | HRP20211528T1 (OSRAM) |
| HU (1) | HUE056608T2 (OSRAM) |
| IL (2) | IL301140A (OSRAM) |
| MA (1) | MA42641A1 (OSRAM) |
| MX (2) | MX2018005048A (OSRAM) |
| MY (1) | MY192278A (OSRAM) |
| NZ (1) | NZ781602A (OSRAM) |
| PE (1) | PE20181167A1 (OSRAM) |
| PH (1) | PH12018500873A1 (OSRAM) |
| PL (1) | PL3365366T3 (OSRAM) |
| RS (1) | RS62437B1 (OSRAM) |
| SG (1) | SG11201803324VA (OSRAM) |
| SI (1) | SI3365366T1 (OSRAM) |
| TW (3) | TWI750139B (OSRAM) |
| UY (1) | UY36965A (OSRAM) |
| WO (1) | WO2017074878A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| WO2019135921A1 (en) * | 2017-12-21 | 2019-07-11 | Aaron Diamond Aids Research Center | Bispecific hiv-1-neutralizing antibodies |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| EP3110844B1 (en) * | 2014-02-28 | 2020-02-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region |
| BR112018008011A2 (en) | 2015-10-25 | 2018-10-30 | Sanofi | trypecific and / or trivalent binding proteins for prevention or treatment of HIV infection |
| CA3003878A1 (en) * | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
| KR20240036142A (ko) | 2016-04-13 | 2024-03-19 | 사노피 | 3특이성 및/또는 3가 결합 단백질 |
| US10882922B2 (en) | 2016-04-13 | 2021-01-05 | Sanofi | Trispecific and/or trivalent binding proteins |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子 |
| BR112019020235A2 (pt) * | 2017-03-27 | 2020-04-22 | Inovio Pharmaceuticals Inc | molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo. |
| WO2018237148A1 (en) * | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
| SG11202003212PA (en) | 2017-10-10 | 2020-05-28 | Sanofi Sa | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies |
| EP3728310A1 (en) * | 2017-12-18 | 2020-10-28 | VIIV Healthcare UK (No.5) Limited | Antigen binding polypeptides |
| US11067584B2 (en) | 2018-01-12 | 2021-07-20 | Genzyme Corporation | Methods for the quantitation of polypeptides |
| EP3797118A4 (en) | 2018-05-22 | 2022-06-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| BR112021006558A2 (pt) * | 2018-10-09 | 2021-07-13 | Sanofi | proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral |
| EP3883962A4 (en) * | 2018-11-21 | 2023-04-12 | Beth Israel Deaconess Medical Center, Inc. | ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) |
| TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| MX2021012386A (es) | 2019-04-09 | 2022-01-18 | Sanofi Sa | Proteínas de union triespecíficas, métodos y usos de las mismas. |
| EP4048690A1 (en) | 2019-10-25 | 2022-08-31 | Sanofi | Methods for analyzing chain mispairing in multispecific binding proteins |
| US20230203466A1 (en) * | 2020-04-03 | 2023-06-29 | Medgenome Inc. | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
| PH12023500005A1 (en) * | 2020-08-25 | 2023-08-14 | Gilead Sciences Inc | Multi-specific antigen binding molecules targeting hiv and methods of use |
| WO2023056313A1 (en) * | 2021-09-29 | 2023-04-06 | Modex Therapeutics | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof |
| CN118317979A (zh) * | 2021-09-29 | 2024-07-09 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| TW202325744A (zh) * | 2021-09-29 | 2023-07-01 | 美商莫德斯醫療公司 | 用於ｈｉｖ之抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| WO2025108551A1 (en) | 2023-11-23 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025109206A1 (en) | 2023-11-22 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| US20250376537A1 (en) | 2024-05-17 | 2025-12-11 | Sanofi | Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2058199T3 (es) | 1987-09-23 | 1994-11-01 | Bristol Myers Squibb Co | Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
| EP2316951A1 (en) | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2011038290A2 (en) | 2009-09-25 | 2011-03-31 | The U. S. A., As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| JP2014502262A (ja) | 2010-11-12 | 2014-01-30 | ザ ロックフェラー ユニバーシティ | Ｈｉｖ治療用の融合タンパク質 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| TWI838039B (zh) | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| US9783594B2 (en) * | 2011-05-17 | 2017-10-10 | The Rockefeller University | Human immunodeficiency virus neutralizing antibodies and methods of use thereof |
| CN104080805B (zh) | 2011-11-07 | 2017-02-22 | 美国政府健康及人类服务部 | gp41中和性抗体及其用途 |
| AU2012336069A1 (en) * | 2011-11-07 | 2014-05-22 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| CA2858716C (en) | 2011-12-08 | 2021-10-12 | Peter D. Kwong | Neutralizing antibodies to hiv-1 and their use |
| WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JP2015529236A (ja) * | 2012-09-25 | 2015-10-05 | グレンマーク ファーマシューティカルズ， エセ．アー． | ヘテロ二量体免疫グロブリンの精製 |
| US9951106B2 (en) | 2012-12-04 | 2018-04-24 | University Of Maryland, Baltimore | Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb |
| MX2015007575A (es) | 2012-12-13 | 2016-03-15 | Univ Pennsylvania | Construcciones de anticuerpos de adn y metodo para utilizarlas. |
| US20140213772A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| AU2014222779B2 (en) | 2013-02-26 | 2018-08-30 | Roche Glycart Ag | Bispecific T cell activating antigen binding molecules |
| BR112015023557A2 (pt) | 2013-03-15 | 2017-10-24 | Abbvie Inc | proteínas de ligações dual específicas direcionadas contra tnfa |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| AU2014296059B2 (en) | 2013-08-02 | 2020-12-10 | The Regents Of The University Of California | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors |
| JP2016538275A (ja) | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| MX385936B (es) | 2014-03-28 | 2025-03-11 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3. |
| CN106687584B (zh) | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物 |
| TN2018000324A1 (en) | 2015-01-23 | 2020-01-16 | Sanofi Sa | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 |
| EP3298389B1 (en) | 2015-05-20 | 2021-09-29 | Quantum-Si Incorporated | Method of determining the sequence of a nucleic acid using time resolved luminescence |
| WO2016196740A1 (en) | 2015-06-02 | 2016-12-08 | The Rockefeller University | Tri-specific antibodies for hiv therapy |
| KR20180050413A (ko) | 2015-09-22 | 2018-05-14 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Hiv 감염을 치료하기 위해 t 세포를 리디렉션시키는 방법 |
| BR112018008011A2 (en) | 2015-10-25 | 2018-10-30 | Sanofi | trypecific and / or trivalent binding proteins for prevention or treatment of HIV infection |
| CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| US10882922B2 (en) | 2016-04-13 | 2021-01-05 | Sanofi | Trispecific and/or trivalent binding proteins |
| KR20240036142A (ko) | 2016-04-13 | 2024-03-19 | 사노피 | 3특이성 및/또는 3가 결합 단백질 |
| WO2018120842A1 (zh) | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子 |
| BR112019020235A2 (pt) | 2017-03-27 | 2020-04-22 | Inovio Pharmaceuticals Inc | molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo. |
| SG11202003212PA (en) | 2017-10-10 | 2020-05-28 | Sanofi Sa | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies |
| BR112021006558A2 (pt) | 2018-10-09 | 2021-07-13 | Sanofi | proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2016
- 2016-10-24 BR BR112018008011-0A patent/BR112018008011A2/en not_active Application Discontinuation
- 2016-10-24 MY MYPI2018701634A patent/MY192278A/en unknown
- 2016-10-24 JP JP2018521308A patent/JP7169190B2/ja active Active
- 2016-10-24 ES ES16794472T patent/ES2894304T3/es active Active
- 2016-10-24 MX MX2018005048A patent/MX2018005048A/es unknown
- 2016-10-24 CN CN202310186776.6A patent/CN116789841A/zh active Pending
- 2016-10-24 EA EA201891028A patent/EA201891028A1/ru unknown
- 2016-10-24 PE PE2018000603A patent/PE20181167A1/es unknown
- 2016-10-24 CR CR20180288A patent/CR20180288A/es unknown
- 2016-10-24 MA MA42641A patent/MA42641A1/fr unknown
- 2016-10-24 EP EP20197556.2A patent/EP3819310A1/en active Pending
- 2016-10-24 SG SG11201803324VA patent/SG11201803324VA/en unknown
- 2016-10-24 HU HUE16794472A patent/HUE056608T2/hu unknown
- 2016-10-24 KR KR1020187014534A patent/KR102687212B1/ko active Active
- 2016-10-24 CN CN201680075852.4A patent/CN109311966B/zh active Active
- 2016-10-24 CA CA3002664A patent/CA3002664A1/en active Pending
- 2016-10-24 WO PCT/US2016/058540 patent/WO2017074878A1/en not_active Ceased
- 2016-10-24 IL IL301140A patent/IL301140A/en unknown
- 2016-10-24 EP EP16794472.7A patent/EP3365366B1/en active Active
- 2016-10-24 NZ NZ781602A patent/NZ781602A/en unknown
- 2016-10-24 RS RS20211266A patent/RS62437B1/sr unknown
- 2016-10-24 CN CN202310185803.8A patent/CN117069855A/zh active Pending
- 2016-10-24 AU AU2016347058A patent/AU2016347058B2/en active Active
- 2016-10-24 CN CN202310147287.XA patent/CN116675776A/zh active Pending
- 2016-10-24 HR HRP20211528TT patent/HRP20211528T1/hr unknown
- 2016-10-24 US US15/770,471 patent/US20190054182A1/en not_active Abandoned
- 2016-10-24 PL PL16794472T patent/PL3365366T3/pl unknown
- 2016-10-24 SI SI201631358T patent/SI3365366T1/sl unknown
- 2016-10-25 TW TW105134405A patent/TWI750139B/zh active
- 2016-10-25 AR ARP160103249A patent/AR106466A1/es unknown
- 2016-10-25 TW TW113100534A patent/TW202442675A/zh unknown
- 2016-10-25 UY UY0001036965A patent/UY36965A/es not_active Application Discontinuation
- 2016-10-25 TW TW110126977A patent/TW202219064A/zh unknown
-
2018
- 2018-04-20 DO DO2018000102A patent/DOP2018000102A/es unknown
- 2018-04-22 IL IL258822A patent/IL258822B2/en unknown
- 2018-04-23 CL CL2018001065A patent/CL2018001065A1/es unknown
- 2018-04-23 PH PH12018500873A patent/PH12018500873A1/en unknown
- 2018-04-24 MX MX2022014631A patent/MX2022014631A/es unknown
- 2018-05-22 CO CONC2018/0005337A patent/CO2018005337A2/es unknown
-
2019
- 2019-10-21 US US16/659,426 patent/US11129905B2/en active Active
-
2021
- 2021-02-04 JP JP2021016190A patent/JP7328267B2/ja active Active
- 2021-08-17 US US17/404,908 patent/US11779651B2/en active Active
-
2023
- 2023-04-06 JP JP2023061823A patent/JP7724814B2/ja active Active
-
2024
- 2024-01-22 AU AU2024200395A patent/AU2024200395A1/en active Pending
- 2024-11-26 US US18/960,890 patent/US20250312475A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023085476A5 (OSRAM) | ||
| JP2018537966A5 (OSRAM) | ||
| JP7724814B2 (ja) | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 | |
| JP2020184996A5 (OSRAM) | ||
| GB2597851A (en) | Antibody molecules that bind to NKP30 and uses thereof | |
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2017537896A5 (OSRAM) | ||
| JPWO2020076853A5 (OSRAM) | ||
| JP2021094022A5 (OSRAM) | ||
| JPWO2020172605A5 (OSRAM) | ||
| JPWO2022102768A5 (OSRAM) | ||
| JPWO2022042488A5 (OSRAM) | ||
| JP2022526826A (ja) | Ｈｉｖ感染症の処置のためのクロスオーバー二重可変ドメイン（ｃｏｄｖ）フォーマットを使用した三重特異性および／または三価結合性タンパク質 | |
| JPWO2022006316A5 (OSRAM) | ||
| JP2022545234A (ja) | Ｃｄ３とｃｄ２０を標的とする二重特異性抗体及びその使用 | |
| JPWO2023056252A5 (OSRAM) | ||
| JPWO2019204398A5 (OSRAM) | ||
| RU2021132277A (ru) | Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv | |
| IL318098A (en) | IGE-FCER pushers | |
| JPWO2022245500A5 (OSRAM) | ||
| WO2022127066A1 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
| NZ742825B2 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| JPWO2022129572A5 (OSRAM) | ||
| JPWO2023045977A5 (OSRAM) |